![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Cresci Sharon
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.6, Iss.15, 2005-12, pp. : 2577-2591
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmacogenetics of the PPAR genes and cardiovascular disease
Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Cavender Matthew A. Lincoff A. Michael
American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
PPAR-γ: Therapeutic Prospects in Parkinson's Disease
Current Drug Targets, Vol. 14, Iss. 7, 2013-06 ,pp. :